Scandiatransplant acceptable mismatch program (STAMP) a bridge to transplanting highly immunized patients

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Pernille Koefoed-Nielsen
  • ,
  • I Weinreich
  • M Bengtsson, Department of Clinical Immunology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden.
  • ,
  • J Lauronen, Finnish Red Cross Blood Service, Helsinki, Finland.
  • ,
  • C Naper, Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
  • ,
  • M Gäbel, University of Gothenburg
  • ,
  • S S Sørensen, Department of Nephrology, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
  • ,
  • L Wennberg, University of Gothenburg
  • ,
  • A V Reisaeter, Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • ,
  • B K Møller
  • Nordic Kidney group and the Tissue Typing group in Scandiatransplant

BACKGROUND: Highly immunized patients are a challenge for organ transplantation programs. One way of increasing the likelihood of transplantation in this group of patients is to expand the possible donations by defining acceptable HLA mismatches. In the Scandiatransplant Acceptable Mismatch Program (STAMP), a de-centralized approach has been implemented in 2009.

AIMS: The program has been improved during the years from utilizing HLA-A, -B, -DR matching only to include typing of all deceased donors for HLA-A, -B, -C, -DRB1 and -DQB1. The calculation of a transplantability score (TS) has been introduced in order to take both HLA and AB0 into consideration resulting in a more realistic picture of the transplantability chance.

MATERIALS AND METHODS: Patients were selected for eligibility and results of immunisation status were prepared in each of the 9 tissue typing laboratories, while access to the program is finally governed by a common steering group of immunologists and clinicians.

RESULTS: In the period from March 2009 until February 2015, 96 patients were transplanted within this program. The mean recipient age was 49 years and 57% were females, 30% of the patients were first transplants and of these 93% were females. The majority of the patients had 2-5 HLA-A, -B. -DR mismatches. The allograft survival at 60 months was 79.1%. Applying the TS to the cohort confirmed that patients with a low TS score had longer waiting times.

CONCLUSION: The program has matured during the years and now proves to be a valid approach for transplanting highly immunized patients.

OriginalsprogEngelsk
TidsskriftHLA
Vol/bind90
Nummer1
Sider (fra-til)17-24
Antal sider8
ISSN2059-2302
DOI
StatusUdgivet - jul. 2017

Se relationer på Aarhus Universitet Citationsformater

ID: 119261294